Promoting Treatment Adherence in nAMD and DME
Experts conclude the series with the hope that longer-acting agents will lead to better real-world outcomes for patients, mirroring clinical trial results and potentially preventing vision loss, especially in countries with limited access to healthcare.
EP: 1.Navigating Step Therapy in nAMD and DME
EP: 2.Role of Biosimilars in nAMD and DME Step Therapy
EP: 3.Overview of the Newest Therapies for AMD and DME: Faricimab and Aflibercept 8mg
EP: 4.Aligning Clinical Trial Retreatment Criteria to Clinical Practice
EP: 5.Perspectives on Retinal Fluid Management in nAMD and DME
EP: 6.Perspectives on Loading Dose and Treatment Extension With New Therapies
EP: 7.Using Steroids in DME Treatment
EP: 8.Patient Selection for New nAMD and DME Therapies
EP: 9.Early Real-World Experiences With Faricimab and Aflibercept 8mg
EP: 10.Safety Considerations for New Therapies
EP: 11.Promoting Treatment Adherence in nAMD and DME
Summary
Experts conclude their discussion reflecting on recent therapeutic advancements and novel approaches on the horizon. As the use of longer durability agents increases, there's optimism that patient adherence to treatment will improve, potentially leading to better real-world outcomes compared to clinical trials. Educating patients about the importance of regular follow-ups and the ongoing nature of treatment is crucial for maintaining adherence. Visual aids like OCT scans can motivate patients by showing the reduction of fluid and improvement in their condition over time. Ultimately, fostering patient buy-in early on and providing ongoing support are key to maximizing treatment effectiveness and preserving vision in conditions like neovascular AMD and diabetic macular edema.
This summary was AI-generated and edited for clarity.
